Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — Australia Biotech + Invest 2020

25 slides from Neuroscientific Biopharmaceuticals's conference presentation, Oct 28, 2020

  1. Slide 1: ASX Announcement: NeuroScientific to present at Australia Biotech + Invest 2020

    For personal use only ASX ANNOUNCEMENT NEUROSCIENFITIC BIOPHARMACEUTICALS TO PRESENT AT AUSTRALIA BIOTECH + INVEST 2020 Perth, Australia; 28 October 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB (“NeuroScientific” or ”the Company”), a drug development company working with novel peptide-based

  2. Slide 2: Novel Drug Therapies for Neurodegenerative Conditions

    NOVEL DRUG THERAPIES FOR For personal use only NEURODEGENERATIVE CONDITIONS Australia Biotech Invest & Partnering 2020 Matt Liddelow, MPharm CEO & Managing Director [email protected]

  3. Slide 3: Disclaimer

    DISCLAIMER The purpose of the presentation is to provide an update of the business of For personal use only NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  4. Slide 4: NeuroScientific Biopharmaceuticals Ltd

    NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD For personal use only NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) is developing peptide-based compounds that prevent neurodegeneration and stimulate neuroregeneration NEUROLOGY Targeted Alzheimer’s disease, Multiple peptides sclerosis, spinal cord injury

  5. Slide 5: Partner / Investment Opportunity

    PARTNER / INVESTMENT OPPORTUNITY For personal use only  EmtinB is modelled on human metallothionein (MT-II) – well known pro survival NOVEL LEAD and regenerative protein COMPOUND  First in-class therapeutic for neurodegenerative conditions  Inhibits cell death (apoptosis), induces regeneration, m

  6. Slide 6: EmtinB: LRP-1 Agonist That Promotes Neuronal Survival & Regeneration

    EMTINB: LRP-1 AGONIST THAT PROMOTES NEURONAL SURVIVAL & REGENERATION For personal use only Binding activity Intracellular signalling ERK H H Lys  Neuronal differentiation Lys OH P13K/Akt  Neuronal survival H Lys  Axonal regeneration Metallothionein-II H  Neuronal plasticity EmtinB LRP-1 CREB  M

  7. Slide 7: Pipeline in a Product

    EMTINB – PIPELINE IN A PRODUCT For personal use only INDICATION RESEARCH IND-ENABLING PHASE I PHASE 2 Alzheimer’s disease NEUROLOGY Multiple sclerosis Glaucoma OPHTHALMOLOGY Optic nerve atrophy Multiple EXPLORATORY indications 6

  8. Slide 8: Neurology

    For personal use only NEUROLOGY

  9. Slide 9: Neurodegenerative Conditions Significantly Contribute to Global Burden of Disease

    NEURODEGENERATIVE CONDITIONS SIGNIFICANTLY CONTRIBUTE TO GLOBAL BURDEN OF DISEASE For personal use only Neurodegeneration involves the progressive loss of neurons, the building blocks of the nervous system DEMENTIA & ALZHEIMER’S DISEASE MULTIPLE SCLEROSIS 50M people globally have dementia 2.5M globa

  10. Slide 10: Promotes Neuronal Survival

    EMTINB PROMOTES NEURONAL SURVIVAL Increases in vitro survival of damaged neurons from different regions of CNS For personal use only CORTEX HIPPOCAMPUS HIPPOCAMPUS: ALZHEIMER’S MODEL 10 9

  11. Slide 11: Promotes Neuronal Regeneration

    EMTINB PROMOTES NEURONAL REGENERATION Increases in vitro axonal regeneration in neurons from different regions of CNS For personal use only CORTEX HIPPOCAMPUS HIPPOCAMPUS: INJURY MODEL SPINAL CORD: INJURY MODEL 11 10

  12. Slide 12: Promotes Remyelination in Multiple Sclerosis Model

    EMTINB PROMOTES REMYELINATION IN MULTIPLE SCLEROSIS MODEL For personal use only Myelination: Increased number of oligodendrocytes MULTIPLE SCLEROSIS MODEL EmtinB, A2B5+ 875%  Oligodendrocytes are support cells that create the EmtinB, MAG+ 607% myelin sheath that insulate axons; demyelination result

  13. Slide 13: Slowed Cognitive Decline in Alzheimer's Model

    EMTINB SLOWED COGNITIVE DECLINE IN ALZHEIMERS MODEL Significantly slowed progression of AD in gold standard mouse model (APPswe/PS1) For personal use only AD MOUSE MODEL Cognition: treatment for 48 days EmtinB 70% +7 ALZHEIMER’S ANIMAL MODEL Control 38% +5  Slowed progression of Alzheimer’s disease

  14. Slide 14: Ophthalmology

    For personal use only OPHTHALAMOLOGY

  15. Slide 15: >5% of Global Population Suffer Vision Loss Due to Damaged Optic Nerve

    >5% OF GLOBAL POPULATION SUFFER VISION LOSS DUE TO DAMAGED OPTIC NERVE For personal use only Optic nerve transmits visual information from the eye to the brain and is composed of 1.7 million nerve fibres GLAUCOMA OPTIC NEURITIS 76M global prevalence 10M global prevalence 2nd leading cause of blindne

  16. Slide 16: Regenerating the Optic Nerve

    REGENERATING THE OPTIC NERVE For personal use only No Treatment cut RAT TRANSECTION MODEL EmtinB precursor compound (MT-II):  Stimulated regeneration of the optic nerve by up to 1000um Treatment (>250% vs non-treated)  Axonal regeneration was evident well beyond the transection site 15

  17. Slide 17: Ocular Tissue Penetration

    EMTINB OCULAR TISSUE PENETRATION Intravitreal delivery demonstrated penetration of the retina and optic nerve head with no cytoxicity For personal use only Retina, 6-hours Optic nerve head, 6-hours OCULAR TISSUE PENETRATION IN RABBITS  Significant concentrations of EmtinB (fluoro-labelled) detected

  18. Slide 18: EmtinB Is Neuroprotective in Glaucoma

    EMTINB IS NEUROPROTECTIVE IN GLAUCOMA Demonstrated neuroprotection in pig model of IOP glaucoma For personal use only GLAUCOMA PIG MODEL  Increased intraocular pressure pig model is the closest % increase experiment to replicate severe human glaucoma pathology; positive results in this model indica

  19. Slide 19: EmtinB Is Neuroprotective in Glaucoma

    EMTINB IS NEUROPROTECTIVE IN GLAUCOMA Demonstrated neuroprotection in pig model of IOP glaucoma NFHp Non-treatment NFHp EmtinB For personal use only GLAUCOMA PIG MODEL  Disruption of cytoskeleton proteins and neurofilaments in neuronal tissue are used as markers for axonal damage Tubulin Non-treatm

  20. Slide 20: Financial Metrics & Milestones

    For personal use only FINANCIAL METRICS & MILESTONES

  21. Slide 21: Financial Metrics & Milestones

    FINANCIAL METRICS & MILESTONES For personal use only FINANCIALS  Completed IPO listing on the ASX July 2018 (ASX: NSB)  >AUS$10 million capital raised since 2016  Currently funded through to completion of Phase 1 safety and tolerability ASX code NSB MILESTONES Shares on issue 78.58M  Q4 2020 – C

  22. Slide 22: Development Plan

    EMTINB DEVELOPMENT PLAN For personal use only 2020 2021 2022 Ph1 ocular safety Q1 2021 Completion of Completion of ocular IND- neurology IND- Ph1 neurology Ph2 Alzheimer’s enabling studies enabling studies safety Ph2 ocular study study Q4 2020 Q1 2021 Q2 2021 Q1 2022 Q2 2022 21

  23. Slide 23: Leadership Team

    LEADERSHIP TEAM For personal use only , MBA Co-founder of ResApp Health 15 years experience Founding director of 20 years’ experience in Ltd (ASX.RAP), Imugene Ltd commercialising medical Actinogen Medical corporate advisory and (ASX:IMU) and Oncosil Ltd devices and pharmaceuticals (ASX:ACW) an adva

  24. Slide 24: Summary Overview

    SUMMARY OVERVIEW NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD (ASX: NSB) For personal use only • Drug development company with an advanced preclinical lead drug candidate called EmtinB; funded through to completion of Phase I in primary treatment indication • EmtinB targets LRP-1 expressed on the outside

  25. Slide 25: For More Information

    FOR MORE INFORMATION: For personal use only Matt Liddelow CEO & Managing Director [email protected] www.neuroscientific.com

NeuroScientific Biopharmaceuticals — Australia Biotech + Invest 2020 on 6ix